Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ

NY‐ESO‐1 is a cancer/testis antigen expressed in various cancer types. However, the induction of NY‐ESO‐1‐specific CTLs through vaccines is somewhat difficult. Thus, we developed a new type of artificial adjuvant vector cell (aAVC‐NY‐ESO‐1) expressing a CD1d‐NKT cell ligand complex and a tumor‐assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujii, Shin‐ichiro, Yamasaki, Satoru, Hanada, Kenichi, Ueda, Shogo, Kawamura, Masami, Shimizu, Kanako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898705/
https://www.ncbi.nlm.nih.gov/pubmed/34971473
http://dx.doi.org/10.1111/cas.15259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898705/
https://www.ncbi.nlm.nih.gov/pubmed/34971473
http://dx.doi.org/10.1111/cas.15259

Ejemplares similares